Characterization of the absorption phase of marijuana smoking

Marilyn A. Huestis, Angela H. Sampson, Barbara J. Holicky, Jack E. Henningfield, Edward J. Cone

Research output: Contribution to journalArticle

Abstract

Rapid blood collection, a paced smoking protocol and timely collection of physiologic and behavioral measures were used to characterize the absorption phase of marijuana smoking. Six healthy males smoked a single marijuana cigarette (placebo, 1.75%, or 3.55% Δ-9-tetrahydrocannabinol) in a double-blind, randomized, Latin square study design. Rapid blood sampling with a continuous withdrawal pump allowed simultaneous collection with concurrent physiologic and behavioral measures. Mean plasma levels of 7.0 and 18.1 ng/ml Δ-9-tetrahydrocannabinol were observed after the first inhalation of a 1.75% and 3.55% Δ-9-tetrahydrocannabinol cigarette, respectively. Blood levels increased rapidly and peaked at 9 minutes, before initiation of the last puff sequence at 9.8 minutes. Three of six subjects reported increases in drug "liking" scores after the first puff, and all subjects responded by the second puff of a high dose cigarette. Significant increases in heart rate and diastolic blood pressure occurred shortly after peak blood levels. Previous studies have indicated that there is a substantial time delay between peak plasma levels of Δ-9-tetrahydrocannabinol and drug-induced effects. This study showed that behavioral and physiologic effects appear concurrently or within minutes after the rapid appearance of Δ-9-tetrahydrocannabinol in blood during marijuana smoking.

Original languageEnglish (US)
Pages (from-to)31-41
Number of pages11
JournalClinical Pharmacology and Therapeutics
Volume52
Issue number1
StatePublished - Jul 1992

Fingerprint

Marijuana Smoking
Dronabinol
Tobacco Products
Blood Pressure
Cannabis
Pharmaceutical Preparations
Inhalation
Heart Rate
Smoking
Placebos

ASJC Scopus subject areas

  • Pharmacology

Cite this

Huestis, M. A., Sampson, A. H., Holicky, B. J., Henningfield, J. E., & Cone, E. J. (1992). Characterization of the absorption phase of marijuana smoking. Clinical Pharmacology and Therapeutics, 52(1), 31-41.

Characterization of the absorption phase of marijuana smoking. / Huestis, Marilyn A.; Sampson, Angela H.; Holicky, Barbara J.; Henningfield, Jack E.; Cone, Edward J.

In: Clinical Pharmacology and Therapeutics, Vol. 52, No. 1, 07.1992, p. 31-41.

Research output: Contribution to journalArticle

Huestis, MA, Sampson, AH, Holicky, BJ, Henningfield, JE & Cone, EJ 1992, 'Characterization of the absorption phase of marijuana smoking', Clinical Pharmacology and Therapeutics, vol. 52, no. 1, pp. 31-41.
Huestis MA, Sampson AH, Holicky BJ, Henningfield JE, Cone EJ. Characterization of the absorption phase of marijuana smoking. Clinical Pharmacology and Therapeutics. 1992 Jul;52(1):31-41.
Huestis, Marilyn A. ; Sampson, Angela H. ; Holicky, Barbara J. ; Henningfield, Jack E. ; Cone, Edward J. / Characterization of the absorption phase of marijuana smoking. In: Clinical Pharmacology and Therapeutics. 1992 ; Vol. 52, No. 1. pp. 31-41.
@article{6a708226433b4acdb1f951297afd6936,
title = "Characterization of the absorption phase of marijuana smoking",
abstract = "Rapid blood collection, a paced smoking protocol and timely collection of physiologic and behavioral measures were used to characterize the absorption phase of marijuana smoking. Six healthy males smoked a single marijuana cigarette (placebo, 1.75{\%}, or 3.55{\%} Δ-9-tetrahydrocannabinol) in a double-blind, randomized, Latin square study design. Rapid blood sampling with a continuous withdrawal pump allowed simultaneous collection with concurrent physiologic and behavioral measures. Mean plasma levels of 7.0 and 18.1 ng/ml Δ-9-tetrahydrocannabinol were observed after the first inhalation of a 1.75{\%} and 3.55{\%} Δ-9-tetrahydrocannabinol cigarette, respectively. Blood levels increased rapidly and peaked at 9 minutes, before initiation of the last puff sequence at 9.8 minutes. Three of six subjects reported increases in drug {"}liking{"} scores after the first puff, and all subjects responded by the second puff of a high dose cigarette. Significant increases in heart rate and diastolic blood pressure occurred shortly after peak blood levels. Previous studies have indicated that there is a substantial time delay between peak plasma levels of Δ-9-tetrahydrocannabinol and drug-induced effects. This study showed that behavioral and physiologic effects appear concurrently or within minutes after the rapid appearance of Δ-9-tetrahydrocannabinol in blood during marijuana smoking.",
author = "Huestis, {Marilyn A.} and Sampson, {Angela H.} and Holicky, {Barbara J.} and Henningfield, {Jack E.} and Cone, {Edward J.}",
year = "1992",
month = "7",
language = "English (US)",
volume = "52",
pages = "31--41",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Characterization of the absorption phase of marijuana smoking

AU - Huestis, Marilyn A.

AU - Sampson, Angela H.

AU - Holicky, Barbara J.

AU - Henningfield, Jack E.

AU - Cone, Edward J.

PY - 1992/7

Y1 - 1992/7

N2 - Rapid blood collection, a paced smoking protocol and timely collection of physiologic and behavioral measures were used to characterize the absorption phase of marijuana smoking. Six healthy males smoked a single marijuana cigarette (placebo, 1.75%, or 3.55% Δ-9-tetrahydrocannabinol) in a double-blind, randomized, Latin square study design. Rapid blood sampling with a continuous withdrawal pump allowed simultaneous collection with concurrent physiologic and behavioral measures. Mean plasma levels of 7.0 and 18.1 ng/ml Δ-9-tetrahydrocannabinol were observed after the first inhalation of a 1.75% and 3.55% Δ-9-tetrahydrocannabinol cigarette, respectively. Blood levels increased rapidly and peaked at 9 minutes, before initiation of the last puff sequence at 9.8 minutes. Three of six subjects reported increases in drug "liking" scores after the first puff, and all subjects responded by the second puff of a high dose cigarette. Significant increases in heart rate and diastolic blood pressure occurred shortly after peak blood levels. Previous studies have indicated that there is a substantial time delay between peak plasma levels of Δ-9-tetrahydrocannabinol and drug-induced effects. This study showed that behavioral and physiologic effects appear concurrently or within minutes after the rapid appearance of Δ-9-tetrahydrocannabinol in blood during marijuana smoking.

AB - Rapid blood collection, a paced smoking protocol and timely collection of physiologic and behavioral measures were used to characterize the absorption phase of marijuana smoking. Six healthy males smoked a single marijuana cigarette (placebo, 1.75%, or 3.55% Δ-9-tetrahydrocannabinol) in a double-blind, randomized, Latin square study design. Rapid blood sampling with a continuous withdrawal pump allowed simultaneous collection with concurrent physiologic and behavioral measures. Mean plasma levels of 7.0 and 18.1 ng/ml Δ-9-tetrahydrocannabinol were observed after the first inhalation of a 1.75% and 3.55% Δ-9-tetrahydrocannabinol cigarette, respectively. Blood levels increased rapidly and peaked at 9 minutes, before initiation of the last puff sequence at 9.8 minutes. Three of six subjects reported increases in drug "liking" scores after the first puff, and all subjects responded by the second puff of a high dose cigarette. Significant increases in heart rate and diastolic blood pressure occurred shortly after peak blood levels. Previous studies have indicated that there is a substantial time delay between peak plasma levels of Δ-9-tetrahydrocannabinol and drug-induced effects. This study showed that behavioral and physiologic effects appear concurrently or within minutes after the rapid appearance of Δ-9-tetrahydrocannabinol in blood during marijuana smoking.

UR - http://www.scopus.com/inward/record.url?scp=0026708683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026708683&partnerID=8YFLogxK

M3 - Article

VL - 52

SP - 31

EP - 41

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 1

ER -